AzurRx BioPharma, Inc.’s (NASDAQ:AZRX) interview with James Sapirstein, Chairman & CEO


See the full episode at:

James Spairstein, Chairman & CEO of AzuRx BioPharma (NASDAQ:AZRX), back again on the show, talking about AZRX’s biopharmaceutical products and therapies. He gives an updated and comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, he provides an update on AZRX’s FDA Phase 2 clinical trials on its lead therapeutic candidate, MS1819 – a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:
Follow New to the Street on Facebook:
Follow New to the Street on Instagram:
Follow New to the Street on Rumble:
About New to the Street:

Subscribe to our Mailing List: